Literature DB >> 31347003

Identification and Interaction Analysis of Key Genes and MicroRNAs in Systemic Sclerosis by Bioinformatics Approaches.

Yan-Hong Sun1,2, Meng Xie1, Shi-di Wu1, Jing Zhang3, Chang-Zheng Huang4.   

Abstract

Systemic sclerosis (SSc) is a highly heterogeneous autoimmune disease with a high mortality rate. However, the cellular and molecular mechanisms of SSc remain unclear. Here, we identified the key hub genes and microRNAs (miRNAs) that modulate the occurrence and development of SSc. We downloaded the microarray dataset GSE95065 from the Gene Expression Omnibus (GEO) database and then analyzed the data by using GEO2R. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used for functional pathway enrichment analyses of differentially expressed genes (DEGs), and Cytoscape software was used to generate the protein-protein interaction (PPI) network. In addition, OmicsNet was used to predict the miRNAs for the hub genes of SSc. As a result, 783 DEGs were identified, of which 770 genes (142 up-regulated genes and 628 down-regulated genes) were matched to the genes in SSc skin samples. Gene Ontology (GO) analyses by DAVID indicated that the up-regulated genes were mainly involved in immune response, and the down-regulated genes were greatly enriched in glycinergic synaptic transmission. In the PPI network, 22 nodes were selected as key genes, including several members of the chemokine family. Furthermore, after uploading these key genes to the OmicsNet tool, we found that hsa-miR-26b-5p might target CXCL9 and CXCL13. Moreover, we demonstrated that the hsa-miR-26b-5p inhibitor might inhibit fibrosis in TGF-β-activated fibroblasts, which would be a promising target for SSc therapy.

Entities:  

Keywords:  CXCL13; CXCL9; bioinformatics analysis; hsa-miR-26b-5p; systemic sclerosis

Mesh:

Substances:

Year:  2019        PMID: 31347003     DOI: 10.1007/s11596-019-2086-3

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  42 in total

1.  Advances in pathogenesis and treatment of systemic sclerosis.

Authors:  Christopher P Denton
Journal:  Clin Med (Lond)       Date:  2016-02       Impact factor: 2.659

2.  MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression.

Authors:  Honglin Zhu; Hui Luo; Yisha Li; Yaou Zhou; Ying Jiang; Jin Chai; Xianzhong Xiao; Yunhui You; Xiaoxia Zuo
Journal:  J Clin Immunol       Date:  2013-05-09       Impact factor: 8.317

3.  CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway.

Authors:  Zhenyu Zhu; Xukui Zhang; Hongliang Guo; Ling Fu; Ganlin Pan; Yinggang Sun
Journal:  Mol Cell Biochem       Date:  2014-12-05       Impact factor: 3.396

Review 4.  Systematic approach to understanding the pathogenesis of systemic sclerosis.

Authors:  Xiaoxia Zuo; Lihua Zhang; Hui Luo; Yisha Li; Honglin Zhu
Journal:  Clin Genet       Date:  2017-03-15       Impact factor: 4.438

Review 5.  Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers.

Authors:  Jammie Barnes; Maureen D Mayes
Journal:  Curr Opin Rheumatol       Date:  2012-03       Impact factor: 5.006

Review 6.  Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches.

Authors:  Joerg Wenzel; Thomas Tüting
Journal:  Exp Dermatol       Date:  2007-05       Impact factor: 3.960

Review 7.  Systemic sclerosis: from pathogenesis to targeted therapy.

Authors:  Christopher P Denton
Journal:  Clin Exp Rheumatol       Date:  2015-10-12       Impact factor: 4.473

8.  Biological network exploration with Cytoscape 3.

Authors:  Gang Su; John H Morris; Barry Demchak; Gary D Bader
Journal:  Curr Protoc Bioinformatics       Date:  2014-09-08

9.  Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC.

Authors:  S Ishikawa; T Sato; M Abe; S Nagai; N Onai; H Yoneyama; Y Zhang ; T Suzuki; S Hashimoto ; T Shirai; M Lipp; K Matsushima
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

Review 10.  CXCL9: evidence and contradictions for its role in tumor progression.

Authors:  Qiang Ding; Panpan Lu; Yujia Xia; Shuping Ding; Yuhui Fan; Xin Li; Ping Han; Jingmei Liu; Dean Tian; Mei Liu
Journal:  Cancer Med       Date:  2016-10-10       Impact factor: 4.452

View more
  5 in total

Review 1.  Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.

Authors:  Chang-Youh Tsai; Song-Chou Hsieh; Tsai-Hung Wu; Ko-Jen Li; Chieh-Yu Shen; Hsien-Tzung Liao; Cheng-Han Wu; Yu-Min Kuo; Cheng-Shiun Lu; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

Review 2.  The Roles of Noncoding RNAs in Systemic Sclerosis.

Authors:  Yongmei Liu; Linlin Cheng; Haoting Zhan; Haolong Li; Xiaomeng Li; Yuan Huang; Yongzhe Li
Journal:  Front Immunol       Date:  2022-04-08       Impact factor: 8.786

3.  Screening and identification of biomarkers for systemic sclerosis via microarray technology.

Authors:  Chen Xu; Ling-Bing Meng; Yu-Chen Duan; Yong-Jing Cheng; Chun-Mei Zhang; Xing Zhou; Ci-Bo Huang
Journal:  Int J Mol Med       Date:  2019-09-05       Impact factor: 4.101

4.  Prediction of severity and subtype of fibrosing disease using model informed by inflammation and extracellular matrix gene index.

Authors:  Amin M Cheikhi; Zariel I Johnson; Dana R Julian; Sarah Wheeler; Carol Feghali-Bostwick; Yvette P Conley; James Lyons-Weiler; Cecelia C Yates
Journal:  PLoS One       Date:  2020-10-23       Impact factor: 3.240

Review 5.  Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis.

Authors:  Chieh-Yu Shen; Cheng-Hsun Lu; Cheng-Han Wu; Ko-Jen Li; Yu-Min Kuo; Song-Chou Hsieh; Chia-Li Yu
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.